MOARF, an Integrated Workflow for Multiobjective Optimization: Implementation, Synthesis, and Biological Evaluation

We describe the development and application of an integrated, multiobjective optimization workflow (MOARF) for directed medicinal chemistry design. This workflow couples a rule-based molecular fragmentation scheme (SynDiR) with a pharmacophore fingerprint-based fragment replacement algorithm (RATS) to broaden the scope of reconnection options considered in the generation of potential solution structures. Solutions are ranked by a multiobjective scoring algorithm comprising ligand-based (shape similarity) biochemical activity predictions as well as physicochemical property calculations. Application of this iterative workflow to optimization of the CDK2 inhibitor Seliciclib (CYC202, R-roscovitine) generated solution molecules in desired physicochemical property space. Synthesis and experimental evaluation of optimal solution molecules demonstrates CDK2 biochemical activity and improved human metabolic stability.

[1]  Sereina Riniker,et al.  Open-source platform to benchmark fingerprints for ligand-based virtual screening , 2013, Journal of Cheminformatics.

[2]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[3]  Stephen D. Roughley,et al.  The Medicinal Chemist′s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates , 2011 .

[4]  Dimitar Hristozov,et al.  Multiobjective De Novo Design of Synthetically Accessible Compounds , 2013 .

[5]  Michael M. Hann,et al.  RECAP — Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry. , 1998 .

[6]  A. Voet,et al.  Fragment based drug design: from experimental to computational approaches. , 2012, Current medicinal chemistry.

[7]  Peter Ertl,et al.  Evaluation of a Semi-Automated Workflow for Fragment Growing , 2015, J. Chem. Inf. Model..

[8]  Jürgen Bajorath,et al.  Matched molecular pairs derived by retrosynthetic fragmentation , 2014 .

[9]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[10]  Nathan Brown,et al.  Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules , 2012, J. Chem. Inf. Model..

[11]  L. R. Dice.  Measures of the Amount of Ecologic Association Between Species , 1945 .

[12]  Isaac M. Westwood,et al.  Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1) , 2013, Journal of medicinal chemistry.

[13]  Markus Hartenfeller,et al.  DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..

[14]  Valerie J. Gillet,et al.  SPROUT: Recent developments in the de novo design of molecules , 1994, J. Chem. Inf. Comput. Sci..

[15]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[16]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[17]  Gregory Landrum,et al.  RDKit: Open-source cheminformatics. Release 2014.03.1 , 2014 .

[18]  Ruth Brenk,et al.  Mining the ChEMBL Database: An Efficient Chemoinformatics Workflow for Assembling an Ion Channel-Focused Screening Library , 2011, J. Chem. Inf. Model..

[19]  Peter Ertl,et al.  IADE: a system for intelligent automatic design of bioisosteric analogs , 2012, Journal of Computer-Aided Molecular Design.

[20]  Thierry Langer,et al.  Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations. , 2006 .

[21]  J. Hughes,et al.  Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.

[22]  Johann Gasteiger,et al.  A Graph-Based Genetic Algorithm and Its Application to the Multiobjective Evolution of Median Molecules. , 2004 .

[23]  Peter J. Fleming,et al.  Combinatorial Library Design Using a Multiobjective Genetic Algorithm , 2002, J. Chem. Inf. Comput. Sci..

[24]  R Scott Obach,et al.  Biotransformation reactions of five-membered aromatic heterocyclic rings. , 2002, Chemical research in toxicology.

[25]  Warren R. J. D. Galloway,et al.  The Basics of Diversity‐Oriented Synthesis , 2013 .

[26]  Nathan Brown,et al.  Multi-objective optimization methods in drug design. , 2013, Drug discovery today. Technologies.

[27]  Sarah R. Langdon,et al.  Scaffold Diversity of Exemplified Medicinal Chemistry Space , 2011, J. Chem. Inf. Model..

[28]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[29]  Constantinos S. Pattichis,et al.  De Novo Drug Design Using Multiobjective Evolutionary Graphs , 2009, J. Chem. Inf. Model..

[30]  Nicholas A. McGrath,et al.  A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives , 2010 .

[31]  Michael T. M. Emmerich,et al.  Multi-Objective Evolutionary Design of Adenosine Receptor Ligands , 2012, J. Chem. Inf. Model..

[32]  Matthew D Segall,et al.  Multi-parameter optimization: identifying high quality compounds with a balance of properties. , 2012, Current pharmaceutical design.

[33]  Johann Gasteiger,et al.  A novel workflow for the inverse QSPR problem using multiobjective optimization , 2006, J. Comput. Aided Mol. Des..

[34]  Yoshimasa Takahashi,et al.  De Novo Design of Drug-Like Molecules by a Fragment-Based Molecular Evolutionary Approach , 2014, J. Chem. Inf. Model..

[35]  Sheng-Yong Yang,et al.  PhDD: a new pharmacophore-based de novo design method of drug-like molecules combined with assessment of synthetic accessibility. , 2010, Journal of molecular graphics & modelling.

[36]  Woody Sherman,et al.  Boosting Virtual Screening Enrichments with Data Fusion: Coalescing Hits from Two-Dimensional Fingerprints, Shape, and Docking , 2013, J. Chem. Inf. Model..

[37]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[38]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[39]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[40]  Tudor I. Oprea,et al.  Chapter 2:Drug-Like Physicochemical Properties , 2011 .

[41]  L Meijer,et al.  CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases , 2008, Oncogene.

[42]  I. Aldoss,et al.  Seliciclib in malignancies , 2009, Expert opinion on investigational drugs.

[43]  Ian Collins,et al.  Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2 , 2013, PloS one.

[44]  Stjepan Uldrijan,et al.  Cyclin-dependent kinase inhibitors as anticancer drugs. , 2010, Current drug targets.

[45]  Paul Workman,et al.  Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. , 2011, Bioorganic & medicinal chemistry.

[46]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[47]  David E. Goldberg,et al.  Genetic algorithms and Machine Learning , 1988, Machine Learning.

[48]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[49]  Luhua Lai,et al.  LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .